1. Kidney FN: K/doqi clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. American Journal of Kidney Diseases 2002, 39:S1-S266.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology : JASN 2004, 15(8):2208-2218.
3. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35(6):1226-1237.
4. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006, 70(7):1358-1366.
5. 张凌，（日）富永芳博: 慢性肾脏病甲状旁腺功能亢进: 科学出版社; 2023.
6. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G et al: GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 2013, 66(2):173-183.
7. Pereira L, Meng C, Marques D, Fraz?o JM: Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clinical kidney journal 2018, 11(1):80-88.
8. Hamano N, Endo Y, Kawata T, Fukagawa M: Development of evocalcet for unmet needs among calcimimetic agents. Expert Rev Endocrinol Metab 2020, 15(5):299-310.
9. Wen T, Wang Z, Chen X, Ren Y, Lu X, Xing Y, Lu J, Chang S, Zhang X, Shen Y et al: Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor. Sci Adv 2021, 7(23).
10. Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE: Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action. Mol Pharmacol 2015, 88(5):853-865.
11. 甘良英: 甲状旁腺激素及其检测方法新进展. 中国血液净化 2016, 15(5):266-268.
12. Torregrosa JV, Bover J, Rodríguez Portillo M, González Parra E, Dolores Arenas M, Caravaca F, González Casaus ML, Martín-Malo A, Navarro-González JF, Lorenzo V et al: Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM). Nefrologia (Engl Ed) 2023, 43 Suppl 1:1-36.
13. 刘志红、李贵森: 中国慢性肾脏病矿物质和骨异常诊治指南. 北京: 人民卫生出版社; 2018.
14. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 2017, 7(1):1-59.
15. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H et al: Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2013, 17(3):247-288.
16. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-266.
17. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC et al: Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clinical journal of the American Society of Nephrology : CJASN 2015, 10(1):98-109.
18. Platt A, Wilson J, Hall R, Ephraim PL, Morton S, Shafi T, Weiner DE, Boulware LE, Pendergast J, Scialla JJ: Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation. Am J Kidney Dis 2024, 83(1):58-70.
19. Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, De Sequera P, Christensson A, Pisoni RL, Robinson BM et al: Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS). BMC nephrology 2018, 19(1):253.
20. Rodriguez M, Salmeron MD, Martin-Malo A, Barbieri C, Mari F, Molina RI, Costa P, Aljama P: A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease. PloS one 2016, 11(1):e0146801.
21. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006, 47(1):149-156.
22. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004, 350(15):1516-1525.
23. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD et al: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology : JASN 2005, 16(3):800-807.
24. Mei C, Chen N, Ding X, Yu X, Wang L, Qian J, Wang M, Jiang G, Li X, Hou F et al: Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Hemodial Int 2016, 20(4):589-600.
25. Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD et al: Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA : the journal of the American Medical Association 2017, 317(2):146-155.
26. Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, Odani M, Akizawa T: A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017, 32(10):1723-1730.
27. Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM et al: Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association 2017, 317(2):156-164.
28. Fukagawa M, Shimazaki R, Akizawa T: Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2018, 94(4):818-825.
29. Ni Z, Liang X, Wu CC, Jin K, Kim YL, Lu KC, Chan TM, Fukagawa M, Kinoshita J, Nagai C et al: Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism. Kidney Int Rep 2023, 8(11):2294-2306.
30. Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T: Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clinical journal of the American Society of Nephrology : CJASN 2023, 18(10):1300-1309.
31. Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM: Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis 2020, 76(3):321-330.
32. Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W et al: Controlled trial of calcitriol in hemodialysis patients. Clinical nephrology 1986, 26(4):185-191.
33. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003, 63(4):1483-1490.
34. Nakai K, Kono K, Yamada S, Taniguchi M, Hamano T, Fukagawa M: Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024.
35. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108(17):2154-2169.
36. Block GA, Chertow GM, Cooper K, Xing S, Fouqueray B, Halperin M, Danese MD: Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodial Int 2021, 25(1):78-85.
37. Smith K, deFilippi C, Isakova T, Gutiérrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R et al: Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis 2013, 61(1):67-73.
38. Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, Allen NB, Scialla JJ, Pencina MJ, Anderson AH et al: Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. Journal of the American Society of Nephrology : JASN 2018, 29(2):579-590.
39. Nielsen TL, Plesner LL, Warming PE, Mortensen OH, Iversen KK, Heaf JG: FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia (Engl Ed) 2019, 39(3):258-268.
40. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW et al: Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 2015, 132(1):27-39.
41. Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R: Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clinical kidney journal 2020, 13(1):75-84.
42. Hidehisa Okamoto YN, Shunsuke Goto, Hayaki Okamoto, Nanako Terada, Kazuo Sakamoto, Keiji Kono and Hideki Fujii: Etelcalcetide improve left ventricular hypertrophy by suppressing the renin-angiotensin-aldosterone system and cardiac fibroblast growth factor 23. In: European Renal Association Congress. 2024.
43. D?rr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R, Beitzke D, Wielandner A, Erben RG, Oberbauer R: Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res 2021, 128(11):1616-1625.
44. D?rr K, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Beitzke D, H?dlmoser S: Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients. Cardiorenal Med 2023, 13(1):332-341.
45. Kuro OM: Phosphate as a Pathogen of Arteriosclerosis and Aging. J Atheroscler Thromb 2021, 28(3):203-213.
46. Yamada S, Nakano T: Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb 2023, 30(8):835-850.
47. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G et al: The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011, 26(4):1327-1339.
48. Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG, Pasch A: Serum calcification propensity predicts all-cause mortality in predialysis CKD. Journal of the American Society of Nephrology : JASN 2014, 25(2):339-348.
49. Górriz JL, Molina P, Cerverón MJ, Vila R, Bover J, Nieto J, Barril G, Martínez-Castelao A, Fernández E, Escudero V et al: Vascular calcification in patients with nondialysis CKD over 3 years. Clinical journal of the American Society of Nephrology : CJASN 2015, 10(4):654-666.
50. Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, Takahashi K, Ota K, Fujii H, Ueda S et al: Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial. Clinical journal of the American Society of Nephrology : CJASN 2021, 16(4):599-612.
51. Toshiki Doi KM, Sonoo Mizuiri, Yoshiko Nishizawa, Takao Masaki: etelcalcetide use affects changes in agataston coronary artery calcium score in maintenance dialysis patients. In: American Society of Nephrology. America; 2023.
52. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW et al: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England journal of medicine 2012, 367(26):2482-2494.
53. Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC et al: The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clinical journal of the American Society of Nephrology : CJASN 2015, 10(5):791-799.
54. Evans M, Methven S, Gasparini A, Barany P, Birnie K, MacNeill S, May MT, Caskey FJ, Carrero JJ: Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci Rep 2018, 8(1):2103.
55. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005, 68(4):1793-1800.
56. Lozano-Ortega G, Waser N, Bensink ME, Goring S, Bennett H, Block GA, Chertow GM, Trotman ML, Cooper K, Levy AR et al: Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. J Comp Eff Res 2018, 7(7):693-707.
57. Zu Y, Lu X, Song J, Yu L, Li H, Wang S: Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis. Kidney Blood Press Res 2019, 44(6):1327-1338.
58. Hung KC, Chang JF, Hsu YH, Hsieh CY, Wu MS, Wu MY, Chiu IJ, Syu RS, Wang TM, Wu CC et al: Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease. International journal of molecular sciences 2020, 21(22).
59. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW et al: Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Journal of the American Society of Nephrology : JASN 2015, 26(6):1466-1475.
60. Khairallah P, Cherasard J, Sung J, Agarwal S, Aponte MA, Bucovsky M, Fusaro M, Silberzweig J, Frumkin GN, El Hachem K et al: Changes in Bone Quality after Treatment with Etelcalcetide. Clinical journal of the American Society of Nephrology : CJASN 2023.
61. Dudar I, Shifris I, Dudar S, Kulish V: Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 2022, 50(299):294-298.
62. Katoh N, Nakayama M, Shigematsu T, Yamamoto H, Sano K, Saito I, Nakano H, Kasai K, Kubo H, Sakai S et al: Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000, 35(3):465-468.
63. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T et al: Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003, 18(12):2613-2621.
64. Monier-Faugere MC, Malluche HH: Calcitriol pulse therapy in patients with end-stage renal failure. Curr Opin Nephrol Hypertens 1994, 3(6):615-619.
65. Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K: Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 2011, 64(9):756-760.
66. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005, 67(2):467-476.
67. Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, Stolina M, Dean C, Jr., Goodman WG, Richards WG et al: Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Calcified tissue international 2017, 101(6):641-653.
68. Yamada S, Tokumoto M, Taniguchi M, Toyonaga J, Suehiro T, Eriguchi R, Fujimi S, Ooboshi H, Kitazono T, Tsuruya K: Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2015, 19(4):367-377.
69. Meola M, Petrucci I, Barsotti G: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009, 24(3):982-989.
70. Lafrance JP, Cardinal H, Leblanc M, Madore F, Pichette V, Roy L, Le Lorier J: Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol 2013, 14:100.
71. Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF: Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS medicine 2013, 10(4):e1001436.
72. 范晓艳, 杨柳, 余永武, 张凌: 西那卡塞治疗维持性血液透析患者不同甲状旁腺激素水平长期疗效评估. 中国血液净化 2022, 21(5):336-340.
73. 张凌, 王文博: 继发性甲状旁腺功能亢进症的不同甲状旁腺切除术式治疗. 中国血液净化 2011, 10(5):236-238.
74. 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会: 慢性肾脏病继发甲状旁腺功能亢进外科临床实践中国专家共识(2021版). 中国实用外科杂志 2021, 41(8):841-848.
75. Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT: Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study. Clin Drug Investig 2008, 28(10):635-643.
76. Wu B, Melhem M, Subramanian R, Chen P, Jaramilla Sloey B, Fouqueray B, Hock MB, Skiles GL, Chow AT, Lee E: Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis. J Clin Pharmacol 2018, 58(6):717-726.
77. Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, Laskin B, Shahinfar S, Vande Walle J, Schaefer F: A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatric nephrology (Berlin, Germany) 2019, 34(3):475-486.
78. Warady BA, Ng E, Bloss L, Mo M, Schaefer F, Bacchetta J: Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatric nephrology (Berlin, Germany) 2020, 35(9):1679-1697.
79. Arenas Morales AJ, DeFreitas MJ, Katsoufis CP, Seeherunvong W, Chandar J, Zilleruelo G, Freundlich M, Abitbol CL: Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. Pediatric nephrology (Berlin, Germany) 2019, 34(1):129-135.
80. Sheerah AA, Al-Ahmed RA, El-Desoky SM, Alhasan KA, Albanna AS, Shalaby MA, Kari JA: Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2021, 32(6):1628-1636.
81. Sohn W, Salusky IB, Schmitt CP, Taylan C, Walle JV, Ngang J, Yan L, Kroenke M, Warady BA: Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatric nephrology (Berlin, Germany) 2021, 36(1):133-142.
82. Xipell M, Montagud-Marrahi E, Rubio MV, Ojeda R, Arias-Guillén M, Fontseré N, Rodas L, Vera M, Broseta JJ, Torregrosa V et al: Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood Purif 2019, 48(2):106-114.
83. Karaboyas A, Muenz D, Fuller DS, Desai P, Lin TC, Robinson BM, Rossetti S, Pisoni RL: Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis 2022, 79(3):362-373.
84. Perrone V, Dovizio M, Veronesi C, Andretta M, Bartolini F, Cavaliere A, Ferrante F, Lupi A, Pagliaro R, Pagnotta R et al: Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting. Healthcare (Basel) 2022, 10(4).
85. Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T: Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. Kidney Int Rep 2021, 6(11):2830-2839.
86. Ure?a-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A: Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2013, 28(5):1241-1254.
87. Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T: Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. PLoS One 2022, 17(2):e0262829.
88. Brunelli SM, Dluzniewski PJ, Cooper K, Do TP, Sibbel S, Bradbury BD: Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Pharmacoepidemiol Drug Saf 2015, 24(10):1058-1067.
89. Tang JKK, Rabkin SW: Hypocalcemia-Induced QT Interval Prolongation. Cardiology 2022, 147(2):191-195.
90. Isbister GK: Risk assessment of drug-induced QT prolongation. Aust Prescr 2015, 38(1):20-24.
91. 拟钙剂在慢性肾脏病患者中应用共识专家组: 拟钙剂在慢性肾脏病患者中应用的专家共识. 中华肾脏病杂志 2018, 34(9):703-708.
92. Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, Walter S, Fitzsimmons M, Wagner M, Soto M et al: Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metab Dispos 2016, 44(8):1319-1331.
93. Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R et al: Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clin Transl Sci 2019, 12(1):20-27.
94. Hoy SM: Upacicalcet: First Approval. Drugs 2021, 81(13):1593-1596.
